Osimertinib 80mg (Osimertinib)

Contact us for more information
Wishlist Compare
Brand nameTagrissoInternational trade nameTagrissoActive substanceOsimertinibStrength80mgCategoryAnti Cancer

Description of Tagrisso 80mg (Osimertinib 80mg)

Tagrisso 80mg (Osimertinib 80mg) tablet is containing an active substance known as Osimeritinib, which is formerly known as Mereletinib.

Tagrisso 80mg (Osimertinib 80mg) is considered as third generation medicine, which is available in tablet form.

Tagrisso 80mg (Osimertinib 80mg) is an inevitable, selectively deviated epidermal growth factor receptor prohibitor, containing anti-cancer activity.
The pharmacological category of Tagrisso 80mg (Osimertinib 80mg) is tyrosine kinase prohibitor.

Medical use /Indication of Tagrisso 80mg (Osimertinib 80mg)

A Tagrisso 80mg (Osimertinib 80mg) tablet is widely indicated as first line therapy for advanced non-small cell lung cancer with EGFR mutation positive patients.

Tagrisso 80mg (Osimertinib 80mg) is also used for the treatment of patients affected with advanced EGFR T792M mutation positive NSCLC, disease has advanced on or after the tyrosine kinase inhibitor treatment.

Mechanism of Action Tagrisso 80mg (Osimertinib 80mg)

Osimeritinib is similar in action when compared to other tyrosine kinase inhibitor medicines.

Osimeritinib is named tyrosine kinase inhibitor of epidermal development factor receptor which is available on the surface of tumor cells

Osimeritinib is non-reversibly converge with mutant type of EGFR at 9 folds than wild sort

Forbids EGFR sharpening changes exon 19 Del and L858R

Prompts denies transformed EGFR with T790M opposition transformation

At last, bring down action against wild kind EGFR

Absorption of Tagrisso 80mg (Osimertinib 80mg)

Peak plasma concentration time of Osimertinib reaches within 6 hours

Distribution of Tagrisso 80mg (Osimertinib 80mg)

Volume of distribution 918L

Plasma protein bound to Osimeritinib is 95%

Metabolism of Tagrisso 80mg (Osimertinib 80mg)

The metabolism of Osimeritinib is occurs through oxidation. The Two pharmacologically active metabolite of Osimeritinib are AZ7550 & AZ5104

Excretion of Tagrisso 80mg (Osimertinib 80mg)

The mean terminal half life period 48 hours Clearance value 14.3L/hr 68% of metabolite is excreted in feces; 14% through urine 2% of unchanged form of medicine is eliminated

Side effects of Tagrisso 80mg (Osimertinib 80mg)

Common side effects :

Fatigue; Lymphocytopenia (Low White Blood Cells); Low Sodium; Shortness of breath; Musculoskeletal Pain; Decreased Appetite; Cough

Less common side effects :

Constipation; Increased serum creatinine; Colitis; Low potassium; Low magnesium; High calcium; Vomiting; Weakness; Diarrhea; High potassium; Low calcium; Swelling; Fever; Rash; Abdominal pain; Increased serum AST; Thrombocytopenia; Increased serum alkaline phosphatase; Chest pain; Weight loss. This are the tagrisso side effects.

Precautions of Tagrisso 80mg (Osimertinib 80mg)

Some of the adverse effects occur during the therapy :

Interstitial lung disease: To avoid this problem, withheld or discontinue the Tagrisso 80mg (Osimertinib 80mg) tablets.

QTc extension: Avoid concurrent use of Tagrisso 80mg (Osimertinib 80mg) with medicine prolong the QTc

Cardiomyopathy: Periodic cardiac monitoring is assessed; in this condition discontinue the therapy.

Keratitis: Monitor the manifestation of keratitis frequently and provide supportive measures

Embryo fetal toxicity: Tagrisso 80mg (Osimertinib 80mg) tablet used in pregnancy period causes fetal damage.

Drug interaction of Tagrisso 80mg (Osimertinib 80mg)

Tagrisso 80mg (Osimertinib 80mg) tablets combines with strong CYP3A4 inducers causes reducing the exposure of Osimeritinib, this may leads to reduce the efficacy of Tagrisso.
Avoid the concomitant use of strong CYP3A4 inducers with Tagrisso 80mg (Osimertinib 80mg)tablets.

Tagrisso 80mg (Osimertinib 80mg) tablet combined with BCRP substrates may causes increasing the exposure of BCRP substrates. Thus results as increasing the adverse effects related to BCRP substrates

Avoid concomitant use of Tagrisso 80mg (Osimertinib 80mg) tablets with medicine which induce the QT prolongation. In this case patients should be undergone periodic ECG monitoring.

Contraindication of Tagrisso 80mg (Osimertinib 80mg)

No contraindication occurred during the therapy

In some patient’s anaphylactic reaction may occur due to patients may contraindicated to the ingredient of the product

Pregnancy of Tagrisso 80mg (Osimertinib 80mg)

Pregnancy category of Osimeritinib is not assigned

While using Tagrisso 80mg (Osimertinib 80mg) tablet causes embryo fetal harm

Lactation of Tagrisso 80mg (Osimertinib 80mg)

Breast feeding should not be suggested

Dosage of Tagrisso 80mg (Osimertinib 80mg)

The usual prescribed dosage of Tagrisso tablets are, 80mg tablet should be taken as a single dose .

Tagrisso 80mg (Osimertinib 80mg) tablet should be administered with or without food.

If patient felt difficult to swallow the Tagrisso 80mg (Osimertinib 80mg)tablets as such, must disperse the tablet in 60ml of noncarbonated water and drink the solution immediately.

Tagrisso tablet do not break, crush or chew.

Discontinue the therapy during the conditions like :

Interstitial lung disease

QT prolongation

Symptomatic congestive heart failure

In pain management

Grade III or severe: Withheld the Tagrisso 80mg (Osimertinib 80mg) tablet for 3 weeks

Grade 0 to II: follow at 80mg or 40mg as a single dose

If no development in 3 weeks: Discontinue the therapy.

While co administration of Tagrisso 80mg (Osimertinib 80mg) with CYP3A4 inducers, the dosage of Tagrisso 80mg (Osimertinib 80mg) should be increased to 160mg as a single dose and followed by 80mg for 3 weeks after discontinuation of strong CYP3A4 inducers.

Storage of Tagrisso 80mg (Osimertinib 80mg)

Tagrisso 80mg (Osimertinib 80mg) tablets should be stored at 25℃ Keep the tablets away from moisture, heat or light.

Missed dose of Tagrisso 80mg (Osimertinib 80mg)

Tagrisso 80mg (Osimertinib 80mg) is a chemo medicine, in case of missed dose occurred skip the missed dose and follow the regular dosing schedule

Brand name:
International trade name:
Active substance:
Anti Cancer
30 Tablet
Product form:

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India